Jennifer A. MacDiarmid

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

Nico van Zandwijk, Nick Pavlakis, Steven Kao et al. · The Lancet Oncology · 2017 · 709 citations

Medicine, Oncology, Pharmacology +15

Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics

Jennifer A. MacDiarmid, Nancy B. Amaro-Mugridge, Jocelyn Weiss et al. · Cancer Cell · 2007 · 302 citations · Full text

Pharmacy, Oncology, Pharmaceutics +14

Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma

Glen Reid, Marcella Pel, Michaela B. Kirschner et al. · Annals of Oncology · 2013 · 276 citations · Full text

Medicine, Cancer Biology, Oncology +14

Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug

Jennifer A. MacDiarmid, Nancy B. Amaro-Mugridge, Jocelyn Madrid-Weiss et al. · Nature Biotechnology · 2009 · 272 citations

Medicine, Oncology, Pharmacology +14

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

James R. Whittle, Jason D. Lickliter, Hui Gan et al. · Journal of Clinical Neuroscience · 2015 · 114 citations

Pharmacy, Oncology, Pharmaceutics +16